Video

There Are Multiple Dynamic Biomarkers for Bladder Cancer

Author(s):

Padmanee Sharma, M.D., Ph.D.

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

When it comes to biomarkers used to determine treatment strategy in bladder cancer, there is more than PD-1, PD-L1 and CTLA-4, says Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Researchers have not yet examined or reached a full understanding of all the possible checkpoints, especially since the targets — like the immune response in general – are very dynamic and change over time.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Related Content
Following the BCG shortage, the first patient with bladder cancer has been dosed with rBCG in the U.S. © freshidea - stock.adobe.com
March 13th 2025

First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer

Spencer Feldman
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Dr. Chandler Park helps patients with genitourinary cancer understand the importance of genetic testing: © lucky - stock.adobe.com
February 28th 2025

There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers

Ryan Scott
Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Image of doctor with brown hair.
February 25th 2025

Some KRAS Mutations Associated With Worse Outcomes in Pancreatic Cancer

Dr. Vaia Florou
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
February 21st 2025

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

Dr. Megan Menon
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.